Psychedelic Therapy: A Primer for Primary Care Clinicians – Part V. Ibogaine
Abstract
<p>Background: Ibogaine is a plant-derived alkaloid that has been used for thousands of years in rites of passage and spiritual ceremonies in West-Central Africa. In the West, it has primarily been used and studied for its anti-addictive properties and more recently for other neuropsychiatric indications, including post-traumatic stress disorder (PTSD), depression, anxiety, and traumatic brain injury (TBI). Areas of Uncertainty: Ibogaine requires careful patient screening and monitoring due to significant safety issues. There is potential for cardiotoxicity (prolonged QT interval); without rigorous screening, fatal arrhythmias may occur. Additionally, ibogaine may have dangerous interactions with opiates, so patients who receive ibogaine treatment for opioid use disorder must withdraw from long-acting opioids. Other potential concerning effects of ibogaine include rare incidents of mania or psychosis. Anticipated transient effects during ibogaine treatment can include ataxia, tremors, and gastrointestinal symptoms.Therapeutic Advances: Nonetheless, robust effects following a single treatment with ibogaine have been reported. In open-label and randomized controlled trials (RCTs), ibogaine reduces heroin and opioid cravings by upwards of 50%, up to 24 weeks after the treatment. Observational studies have shown that ibogaine, in combination with the psychedelic 5-methoxy-dimethyltryptamine (5-MeO-DMT), significantly diminishes PTSD (d = 0.414) and depression symptoms (d = 0.275). Treatment clinics have opened in countries where ibogaine is either legal or unregulated for people struggling with substance use disorders or refractory distress. <h4>Conclusions:</h4> Given the promising preliminary findings, ibogaine could potentially fill a much-needed gap in treatments for challenging conditions, including opioid dependence and combat-related symptom complexes. However, there is currently a lack of rigorous research, such as double-blind, placebo-controlled RCTs, to support ibogaine’s safety and efficacy. It is imperative to develop practices that reduce patient risk and improve treatment sustainability, given high rates of ibogaine trafficking.</p>
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.